The Use of Contrast Agents in Interventional Pain Procedures: A Multispecialty and Multisociety Practice Advisory on Nephrogenic Systemic Fibrosis, Gadolinium Deposition in the Brain, Encephalopathy After Unintentional Intrathecal Gadolinium Injection, and Hypersensitivity Reactions.
Brain
/ drug effects
Brain Diseases
/ chemically induced
Consensus
Contrast Media
/ administration & dosage
Delphi Technique
Drug Hypersensitivity
/ diagnosis
Humans
Nephrogenic Fibrosing Dermopathy
/ chemically induced
Pain Management
/ adverse effects
Prognosis
Risk Assessment
Risk Factors
Tissue Distribution
Journal
Anesthesia and analgesia
ISSN: 1526-7598
Titre abrégé: Anesth Analg
Pays: United States
ID NLM: 1310650
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
24
3
2021
medline:
14
9
2021
entrez:
23
3
2021
Statut:
ppublish
Résumé
This Practice Advisory presents a comprehensive and evidence-based set of position statements and recommendations for the use of contrast media in interventional pain procedures. The advisory was established by an international panel of experts under the auspices of 11 multinational and multispecialty organizations based on a comprehensive review of the literature up to December 31, 2019. The advisory discusses the risks of using gadolinium-based contrast agents. These include nephrogenic systemic fibrosis, gadolinium brain deposition/retention, and encephalopathy and death after an unintentional intrathecal gadolinium injection. The advisory provides recommendations on the selection of a specific gadolinium-based contrast agent in patients with renal insufficiency, those who had multiple gadolinium-enhanced magnetic resonance imaging examinations, and in cases of paraspinal injections. Additionally, recommendations are made for patients who have a history of mild, moderate, or severe hypersensitivity reactions to contrast medium.
Identifiants
pubmed: 33755647
doi: 10.1213/ANE.0000000000005443
pii: 00000539-202108000-00031
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Practice Guideline
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-552Informations de copyright
Copyright © 2021 International Anesthesia Research Society.
Déclaration de conflit d'intérêts
Conflicts of Interest: See Disclosures at the end of the article.
Références
Runge VM, Ai T, Hao D, Hu X. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011;46:807–816.
ACR Committee on Drugs and Contrast Media. ACR manual on contrast media, version 10.3. 2018. Accessed May 20, 2020. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast-Media.pdf
Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology. 2010;256:735–743.
Thomsen HS. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1. Acta Radiol. 2016;57:515–520.
Kanda T, Oba H, Toyoda K, Kitajima K, Furui S. Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol. 2016;34:3–9.
Olchowy C, Cebulski K, Łasecki M, et al. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity -a systematic review. PLoS One. 2017;12:e0171704.
Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent otn the class of contrast agent. Radiology. 2015;275:783–791.
Arlt S, Cepek L, Rustenbeck HH, Prange H, Reimers CD. Gadolinium encepalopathy due to accidental intrathecal administration of gadopentetate dimeglumine. J Neurol. 2007;2564:810–812.
Popescu A, Patel J, McCormick ZL, et al.; on behalf of the Patient safety Committee of the Spine Intervention Society. FactFinders for patient safety: are gadolinium-based contrast media safe alternatives to iodinated contrast agents for the safe performance of spinal injection procedures? Pain Med. 2018;19:2089–2090.
Provenzano D, Pellis Z, DeRiggi L. Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: a case report and a comprehensive evidence-based review. Reg Anesth Pain Med. 2019;44:721–729.
Benzon HT, Liu BP, Patel AS, Benzon HA. Caution in using gadolinium-based contrast agents in interventional pain procedures. Anesth Analg. 2018;127:1452–1456.
Durbhakula S, Cohen SP. Gadolinium use for interventional procedures: where we are and where are we heading. Reg Anesth Pain Med. 2019;44:118–121.
Maus T. Intrathecal gadolinium: a fatal flaw. Reg Anesth Pain Med. 2019;44:687–688.
Benzon HT, Schecthman J, Zheng S, et al. Patients with a history of adverse reaction to iodinated contrast medium and given iodinated contrast during an interventional procedure. Reg Anesth Pain Med. 2019;44:118–121.
Manchikanti L, Pampati V, Hirsh J. Retrospective cohort study of usage patterns of epidural injections for spinal pain in the US fee-for-service Medicare population from 2000 to 2014. BMJ Open. 2016;6:e013042.
Benzon HT, Joshi G, Gan TJ, Vetter T. Development, reporting and evaluation of clinical practice guidelines. Anesth Analg. 2019;129:1771–1777.
US Preventive Services Task Force Grade Definitions after July 2012. Levels of certainty Regarding Net Benefit. Accessed January 5, 2020. https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what is s and what it isn’t. BMJ. 1996;312:71–72.
Djulbegovic B, Guyatt G. Evidence vs consensus in clinical practice guidelines. JAMA. Published online July 19, 2019. doi: 10.1001/jama.2019.9751.
doi: 10.1001/jama.2019.9751
Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Updated clinical practice guideline on use of gadolinium-based contrast agents in kidney disease issued by the Canadian Association of Radiologists. Can Assoc Radiol J. 2019;70:226–232.
Malayeri AA, Brooks KM, Bryant LH, et al. National Institutes of Health perspective on reports of gadolinium deposition in the brain. J Am Coll Radiol. 2016;13:237–241.
Gulani V, Calamante F, Shellock FG, et al. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16:564–570.
Todd DJ, Kay J. Gadolinium-induced fibrosis. Annu Rev Med. 2016;67:273–291.
Evans CH, Drouven BJ. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J. 1983;213:751–758.
Brouven BJ, Evans CH, Evans CH. Collagen fibrillogenesis in the presence of lanthanides. J Biol Chim. 1986;261:11792–11797.
Thomsen HS, Morcos SK, Almen T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23:307–318.
Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65:1095–1106.
Schieda N, van der Pol CB, Walker D, et al. Adverse events to the gadolinium-based contrast agent gadoxetic acidsystematic review and meta-analysis. Radiology. 2020;297:565–572.
European Society of Urogenital Radiology. ESUR guidelines on contrast agents, version10.0. 2018. Accessed May 20, 2020. http://www.esur-cm.org/index.php/a-general-adverse-reactions-2
Woolen SA, Shankar PR, Gagnier JJ, et al. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med. 2020;180:223–230.
Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294:660–668.
Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenada D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834–841.
Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: Evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276:228–232.
Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015;275:803–809.
McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772–782.
Murata M, Gonzalez-Cuyar LF, Murata K, et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from patients with normal renal function. Invest Radiol. 2016;51:447–453.
Murata M, Murata K, Gonzalez-Cuyar LF, Maravilla KR. Gadolinium tissue deposition in brain and bone. Magn Reson Imaging. 2016;34:1359–1365.
Roberts DR, Lindhorst SM, Welsh CT, et al. High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol. 2016;51:280–289.
FDA Drug Safety Podcast: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. Accessed October 1, 2020. https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body-requires#:~:text=On%20December%2019%2C%202017%2C%20FDA,years%20after%20receiving%20these%20drugs
Update on FDA approach to safety issue of gadolinium retention after administration of gadolinium-based contrast agents. Accessed October 1, 2020. https://www.fda.gov/media/116492/download
Levine D, McDonald RJ, Kressel HY. Gadolinium retention after contrast-enhanced MRI. JAMA. 2018;320:1853–1854.
Burke LM, Ramalho M, AlObaidy M, Chang E, Jay M, Semelka RC. Self-reported gadolinium toxicity: a survey of patients with chronic symptoms. Magn Reson Imaging. 2016;34:1078–1080.
Welk B, McArthur E, Morrow SA, et al. Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA. 2016;316:96–98.
McDonald RJ, Levine D, Weinred J, et al. Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology. 2018;289:517–534.
Costa AF, van der Pol CV, Maralani PJ, et al. Gadolinium deposition in the brain: a systematic review of existing guidelines and policy statement issued by the Canadian Association of Radiologists. Can Assoc Radiol J. 2018;69:373–82.
Oner AY, Barutcu B, Aykoll S, Talli ET. Intrathecal contrast-enhanced magnetic resonance imaging-related brain signal changes: residual gadolinium deposition? Invest Radiol. 2017;52:195–197.
Kapoor R, Liu J, Devasenapathy A, Gordin V. Gadolinium encephalopathy after intrathecal gadolinium injection. Pain Physician. 2010;13:E321–E326.
Reeves C, Galang E, Padalia R, Tran N, Padalia D. Intrathecal injection of gadobutrol: a tale of caution. J Pain Palliat Care Pharmacother. 2017;31:139–143.
Arlt S, Cepek L, Rustenbeck HH, Prange H, Reimers CF. Gadolinium encephalopathy due to accidental intrathecal administration of gadopentetate gimeglumine. J Neurol. 2007;254:810–812.
Li L, Gao FQ, Zhang B, et al. Overdosage of intrathecal gadolinium and neurological response. Clin Radiol. 2008;63:1063–1068.
Park K-W, Im S-B, Kim B-T, et al. Neurotoxic manifestations of an overdose intrathecal injection of gadopentetate dimeglumine. J Korean Med Sci. 2010;25:505–508.
Nayak NB, Huang JC, Hathout GM, et al. Complex imaging features of accidental cerebral intraventricular gadolinium administration. J Neurosurg. 2013;118:1130–1134.
Nehra AK, McDonald RJ, Bluhm AM, et al. Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: a prospective observational cohort study. Radiology. 2018;288:416–423.
Berger F, Kubik-Huch RA, Niemann T, et al. Gadolinium-distribution in cerebrospinal fluid after administration of a gadolinium-based MR contrast agent in humans. Radiology. 2018;288:703–709.
Albayram S, Kilic F, Ozer H, et al. Gadolinium-enhanced MR cisternography to evaluate dural leaks in intracranial hypotension syndrome. AJNR Am J Neuroradiol. 2008;29:116–121.
Algin O, Turkbey B. Intrathecal gadolinium-enhanced MR cisternography:a comprehensive review. AJNR Am J Neuroradiol. 2013;34:14–22.
Edeklev CS, Halvorsen M, Lovland G, et al. Intrathecal use of gadobutrol for glymphatic MR imaging: prospective safety study of 100 patients. AJNR Am J Neuroradiol. 2019;40:1257–1264.
Dillon WP. Intrathecal gadolinium: its time has come? AJNR Am J Neuroradiol. 2008;29:3–4.
Vogler H, Platzek J, Schuhmann-Giamperi G, et al. Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol. 1995;21:1–10.
El-Yahchouchi CA, Plastaras CT, Maus TP, et al. Adverse event rates associated with transforaminal and interlaminar epidurals injections: a multi-institutional study. Pain Med. 2016;17:239–249.
Popescu A, McCormick ZL, Smith CC. Spine Intervention Society’s Patient Safety Committee. Strategies to minimize risk in lumbar transforaminal injections: Imaging and injectate. Pain Med. 2019;20:1449–1450.
Maus TP, Schueler BA, Magnuson DJ, Magnuson D. Relative conspicuity of gadolinium-based contrast agents in interventional pain procedures. Pain Med. 2017;18:651–654.
Costello JR, Kalb B, Martin DR. Incidence and risk factors for gadolinium-based contrast agent immediate reactions. Top Magn Reason Imaging. 2016;25:257–263.
Kim MH, Lee SY, Lee SE, et al. Anaphylaxis to iodinated contrast media: clinical characteristics related with development of anaphylactic shock. PLoS One. 2014;9:e100154.
Morzycki A, Bhatia A, Murphy K. Adverse reactions to contrast material: a Canadian update. Can Assn Radiol J. 2017;68:187–193.
Masch WR, Wangl CL, Davenport MS. Severe allergic-like contrast reactions: epidemiology and appropriate treatment. Abd Radiol. 2016;41:1632–1639.
Bohm I, Morelli J, Nairz K, et al. Myths and misconceptions concerning contrast media-induced anaphylaxis: a narrative review. Postgrad Med. 2017;129:259–266.
Mayorga C, Fernandez TD, Montañez MI, Moreno E, Torres MJ. Recent developments and highlights in drug hypersensitivity. Allergy. 2019;74:2368–2381.
Sánchez-Borges M, Aberer W, Brockow K, et al. Controversies in drug allergy: radiographic contrast media. J Allergy Clin Immunol Pract. 2019;7:61–65.
Cha MJ, Kang DY, Lee W, et al. Hypersensitivity reactions to iodinated contrast media: a multicenter study of 196 081 patients. Radiology. 2019;293:117–124.
Schabelman E, Witting M. The relationship of radiocontrast, iodine, and seafood allergies: a medical myth exposed. J Emerg Med. 2010;39:701–707.
Long B, Chassee T, Jones JS. BET 2: is there an association between iodine, shellfish and contrast agent allergies? Emerg Med J. 2019;36:698–699.
Smith MA, Newton LP, Barcena Blanch MA, et al. Risk for anaphylactic reaction from cardiac catheterization in patients receiving β-adrenergic blockers or angiotensin converting enzyme-inhibitors. J Allergy Clin Immunol Pract. 2020;8:1900–1905.
Wang CL, Cohan CH, Ellis JH, Caoili EM, Wang G, Francis JR. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol. 2008;191:409–415.
Mortele KJ, Oliva MR, Ondategui S, Ros PR, Silverman SG. Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital. AJR Am J Roentgenol. 2005;185:31–34.
Behzadi AH, Zhao Y, Farooq Z, Prince MR. Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology. 2018;286:471–482.
Jung JW, Kang HR, Kim MH, et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology. 2012;264:414–422.
McDonald JS, Hunt CH, Kolbe AB, et al. Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281945 injections. Radiology. 2019;292:620–627.
Davenport MS. Choosing the safest gadolinium-based contrast medium for MR imaging: not so simple after all. Radiology. 2018;286:483–485.
Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol. 1991;87:867–872.
Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med. 1987;317:845–849.
Park HJ, Park JW, Yang MS, et al. Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: A multicentre retrospective cohort study. Eur Radiol. 2017;27:2886–2893.
Jung JW, Choi YH, Park CM, et al. Outcomes of corticosteroid prophylaxis for hypersensitivity reactions to low osmolar contrast media in high-risk patients. Ann Allerg Asthma Immunol. 2016;117:304–309.
Park SJ, Kang DY, Sohn KH, et al. Immediate mild reactions to CT with iodinated contrast media: strategy of contrast media readministration without corticosteroids. Radiology. 2018;288:710–716.
Abe S, Fukuda H, Tobe K, Ibukuro K. Protective effect against repeat adverse reactions to iodinated contrast medium: premedication vs. changing the contrast medium. Eur Radiol. 2016;26:2148–2154.
Park SJ, Lee SY, Yoon SH, Choi YH, Kang HR. Corticosteroid prophylaxis may be not required for patients with mild hypersensitivity reaction to low-osmolar contrast media. Eur J Radiol. 2020;130:109152.
Tramer MR, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ. 2006;333:675–681.
Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol. 2001;176:1389–1392.
Davenport MS, Cohn RH, Caoili EM, Ellis JH. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology. 2009;253:372–379.
Davenport MS, Cohan RH. The evidence for and against corticosteroid prophylaxis in at-risk patients. Radiol Clin North Am. 2017;55:413–421.
Fok JS, Smith WB. Hypersensitivity reactions to gadolinium-based contrast agents. Curr Opin Allergy Clin Immunol. 2017;17:241–246.
Tardy B, Guy C, Barral G, et al. Anaphylactic shock induced by intravenous gadopentetate dimeglumine. Lancet. 1992;339:494.
Dillman JR, Ellis JH, Cohan RH, et al. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. Am J Roentgenol. 2008;190:187.
Kim YS, Choi YH, Cho YJ, et al. Incidence of breakthrough reaction in patients with prior acute allergic-like reactions to iodinated contrast media according to the administration route. Korean J Radiol. 2018;19:352–357.
Benzon HT, Schecthman J, Zheng S, et al. Patients with a history of adverse reaction to iodinated contrast medium and given iodinated contrast during an interventional procedure. Reg Anesth Pain Med. 2019;44:118–121.
Mishra RK, Heavner JE, Day M. Prevalence of adverse reactions to radiopaque contrast reported by patients presenting for interventional pain procedure. Pain Pract. 2012;13:182–190.
Carr CM, Plastaras CT, Pingree MJ, et al. Immediate adverse events in interventional pain procedures: a multi-institutional study. Pain Med. 2016;17:2155–2161.
Kalangara J, Lanier K, Beckworth W, Kuruvilla M. Absence of iodinated contrast hypersensitivity and characterization of gadolinium utilization in an interventional pain population. Pain Pract. 2021;21:184–189..
Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy. 2009;64:234–241.
Greenberger P. Hypersensitivity reactions to iodinated radiocontrast media: to skin test or not to skin test. J Allergy Clin Immunol Pract. 2018;6:1255–1256.
Bridenbaugh PO. Office-based anesthesia: requirements for patient safety. Anesth Prog. 2005;52:86–90.
Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA. 2009;301:868–869.
Kahn R, Gale EA. Gridlocked guidelines for diabetes. Lancet. 2010;375:2203–2204.
Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327:1459–1461.